A Comparative Systematic Review of the Efficacy and Safety of Shengxuening(SXN) for Anemia in chronic kidney disease

Objective To assess the efficacy and safety of Shengxuening(SXN)for renal anemia.Methods All randomized trials(RCTs) of SXN for renal anemia were collected from CNKI,CBM,Wan Fang Database,Springer and Pub Med.Two reviewers independently screened the included studies,extracted the data,assessed the q...

Full description

Saved in:
Bibliographic Details
Main Authors: ZHANG Lei, ZHANG Wen-jin, JIN Hua, WANG Dong, WEI Ling, WANG Li-yuan, WANG Yi-ping
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Nephrology 2015-01-01
Series:Linchuang shenzangbing zazhi
Subjects:
Online Access:http://www.lcszb.com/thesisDetails?columnId=57921282&Fpath=home&index=0
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To assess the efficacy and safety of Shengxuening(SXN)for renal anemia.Methods All randomized trials(RCTs) of SXN for renal anemia were collected from CNKI,CBM,Wan Fang Database,Springer and Pub Med.Two reviewers independently screened the included studies,extracted the data,assessed the quality,and cross-checked.Then RevMan5.01 software was used for meta-analysis.Results A total of 5 RCTs were enrolled in the review.The results of meta-analysis showed that as compared with the control group,hemoglobin[WMD = 13.14,95%CI(7.74,18.54),P<0.00001],serum ferritin[WMD=8.32,95%CI(2.21,14.42),P<0.00001]and transferrin saturation[WMD=22.35,95%CI(63.64,181.06),P<0.00001]were significantly increased in SXN group.The adverse reactions were reported in all researches.The total adverse rate in SXN group and control group was 1.74%and 13.37%respectively[OR=0.09,95%CI(0.03,0.25),P<0.00001].Conclusions The researches currently available show that SXN has more efficacy and safety in elevating the level of serum ferritin,transferrin saturation and hemoglobin than ferrous sulfate/ferrous succinate.However,double-blinded RCTs are needed to access the SXN for patients’ end point target including lifetime,risk of cardiovascular events and dialysis time.
ISSN:1671-2390